{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Bafna Pharmaceuticals Ltd
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 162.07, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5% on 19 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5.0% Gain — Buyers Queue, Sellers Absent
At Rs 156.79, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 17 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Bafna Pharmaceuticals Ltd Locks at Lower Circuit With 4.99% Loss — Sellers Queue, No Buyers in Sight
At Rs 149.33, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 4.99% on 16 Jun 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.
Bafna Pharmaceuticals Ltd Locks at Lower Circuit With 5.0% Loss — Sellers Queue, No Buyers in Sight
At Rs 157.18, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 5.0% on 15 Jun 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance between supply and demand in this micro-cap stock.
Bafna Pharmaceuticals Gains 33.40%: 5 Key Factors Driving the Surge
Bafna Pharmaceuticals Ltd delivered a remarkable 33.40% gain over the week ending 5 June 2026, driven by five consecutive days of upper circuit hits amid strong buying momentum. This surge starkly contrasted with the Sensex’s 0.78% decline over the same period, highlighting the stock’s exceptional outperformance despite its micro-cap status and a cautious ‘Sell’ mojo grade. However, valuation concerns emerged midweek, signalling potential challenges ahead for investors.
Bafna Pharmaceuticals Drops 6.99%: 7 Key Events Shaping the Week
Bafna Pharmaceuticals Ltd experienced a turbulent trading week from 8 to 12 June 2026, ending with a 6.99% decline to close at Rs.166.25, while the Sensex gained 0.57%. The stock’s journey was marked by sharp swings, including two upper circuit hits early in the week followed by three consecutive lower circuit hits, reflecting intense volatility and shifting investor sentiment amid mixed technical and fundamental signals.
Bafna Pharmaceuticals Ltd Locks at Lower Circuit With 5.0% Loss — Sellers Queue, No Buyers in Sight
At Rs 165.45, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 5.0% on 12 Jun 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.
Bafna Pharmaceuticals Ltd Locks at Lower Circuit With 5.0% Loss — Sellers Queue, No Buyers in Sight
At Rs 157.57, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 5.0% on 11 Jun 2026, with unfilled sell orders and a frozen price, signalling a day dominated by supply overwhelming demand.
Bafna Pharmaceuticals Ltd Forms Golden Cross Amid Mixed Technical Signals and Recent Price Drop
The 50-day moving average has crossed above the 200-day moving average for Bafna Pharmaceuticals Ltd, signalling a golden cross on 10 Jun 2026. However, the stock declined 4.97% on the day the cross formed, while some technical indicators present a mixed picture. This divergence between the moving averages and price action calls for a closer examination of the signal's reliability.
Bafna Pharmaceuticals Ltd is Rated Sell
Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 10 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Bafna Pharmaceuticals Ltd Locks at Lower Circuit With 4.99% Loss — Sellers Queue, No Buyers in Sight
At Rs 165.86, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 4.99% on 10 Jun 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock with limited liquidity.
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 10% Gain — Buyers Queue, Sellers Absent
At Rs 213.36, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 10% on 9 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Broad-Based Technical Strength Lifts Bafna Pharmaceuticals Ltd to 52-Week High of Rs 215.7
Surging past its previous peaks, Bafna Pharmaceuticals Ltd touched a fresh 52-week high of Rs 215.7 on 09 Jun 2026, marking a remarkable rally of 186.47% over the past year. This milestone comes amid a sustained seven-day winning streak, underscoring the stock’s robust momentum despite a broadly subdued market backdrop.
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 10.0% Gain — Buyers Queue, Sellers Absent
At Rs 193.97, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 10.0% on 8 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 160.31, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5% on 4 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Above All Moving Averages and Now at Upper Circuit: Bafna Pharmaceuticals Ltd Gains 5.0% in a Single Session
At Rs 152.68, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 3 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges
Bafna Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating, raising questions about its price attractiveness relative to historical levels and peer benchmarks. Despite a recent 4.98% intraday gain, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest investors should carefully reassess its market positioning within the Pharmaceuticals & Biotechnology sector.
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 145.41, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5% on 2 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5.09% Gain — Buyers Queue, Sellers Absent
At Rs 138.49, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.09% on 1 Jun 2026, with buyers queuing and no sellers willing to part with shares.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
